Revenue
No reported data
Sanofi (SNY)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | €33.67B | €31.08B | €28.99B | €28.68B | €26.92B | €25.21B | €25.65B | €24.24B | €24.61B | €24.00B | €23.94B |
| Research & development | €7.84B | €7.39B | €6.51B | €6.50B | €5.69B | €5.53B | €6.02B | €5.89B | €5.47B | €5.17B | €5.08B |
| Operating income | €6.34B | €7.25B | €6.96B | €10.16B | €8.13B | €14.11B | €3.05B | €4.68B | €5.80B | €6.53B | €5.62B |
| Net income | €7.81B | €5.56B | €5.40B | €8.37B | €6.22B | €12.29B | €2.75B | €4.31B | €8.42B | €4.71B | €4.29B |
| Basic EPSper diluted share | €6.40 | €4.44 | €4.31 | €6.69 | — | €9.82 | €2.24 | €3.45 | €6.70 | €3.66 | €3.28 |
| Diluted EPSper diluted share | €6.37 | €4.43 | €4.30 | €6.66 | — | €9.77 | €2.23 | €3.43 | €6.64 | €3.63 | €3.25 |